UCLA and Leica Biosystems to collaborate in digital pathology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The UCLA Department of Pathology and Laboratory Medicine and Leica Biosystems will collaborate in digital pathology.

Product testing will be conducted with UCLA to validate digital pathology in a high-volume setting. This joint effort builds upon the existing relationship between UCLA and Leica Biosystems that was established in 2011.

The pathology team at UCLA will be working with Leica Biosystems Aperio ePathology and will test and provide quantitative feedback on current and next-generation products from bench research to full clinical adoption.

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login